Larimar Therapeutics, Inc. (LRMR)
3.32
-0.54
(-14.10%)
USD |
NASDAQ |
Sep 24, 16:00
3.32
0.00 (0.00%)
After-Hours: 19:59
Larimar Therapeutics Enterprise Value : 195.24M for Sept. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 24, 2026 | 195.24M |
| September 23, 2026 | 252.13M |
| September 22, 2026 | 247.43M |
| September 21, 2026 | 248.48M |
| September 18, 2026 | 244.30M |
| September 17, 2026 | 245.34M |
| September 16, 2026 | 258.91M |
| September 15, 2026 | 256.83M |
| September 14, 2026 | 243.26M |
| September 11, 2026 | 257.87M |
| September 10, 2026 | 250.56M |
| September 09, 2026 | 252.65M |
| September 08, 2026 | 274.05M |
| September 04, 2026 | 248.48M |
| September 03, 2026 | 248.48M |
| September 02, 2026 | 252.65M |
| September 01, 2026 | 259.96M |
| August 31, 2026 | 247.43M |
| August 28, 2026 | 267.27M |
| August 27, 2026 | 271.44M |
| August 26, 2026 | 283.97M |
| August 25, 2026 | 282.92M |
| August 24, 2026 | 271.44M |
| August 21, 2026 | 285.01M |
| August 20, 2026 | 282.92M |
| Date | Value |
|---|---|
| August 19, 2026 | 292.32M |
| August 18, 2026 | 272.48M |
| August 17, 2026 | 299.62M |
| August 14, 2026 | 303.80M |
| August 13, 2026 | 294.40M |
| August 12, 2026 | 304.84M |
| August 11, 2026 | 298.58M |
| August 10, 2026 | 267.27M |
| August 07, 2026 | 282.92M |
| August 06, 2026 | 287.10M |
| August 05, 2026 | 276.66M |
| August 04, 2026 | 277.70M |
| August 03, 2026 | 264.13M |
| July 31, 2026 | 247.43M |
| July 30, 2026 | 247.95M |
| July 29, 2026 | 227.60M |
| July 28, 2026 | 248.48M |
| July 27, 2026 | 248.48M |
| July 24, 2026 | 266.22M |
| July 23, 2026 | 267.27M |
| July 22, 2026 | 268.31M |
| July 21, 2026 | 258.91M |
| July 20, 2026 | 248.48M |
| July 17, 2026 | 234.91M |
| July 16, 2026 | 231.78M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.935B |
| Alnylam Pharmaceuticals, Inc. | 33.06B |
| Anika Therapeutics, Inc. | 257.58M |
| Savara, Inc. | 898.75M |
| Vericel Corp. | 1.943B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -32.78M |
| Total Expenses (Quarterly) | 32.78M |
| EPS Diluted (Quarterly) | -0.3141 |
| Earnings Yield | -59.73% |
| Normalized Earnings Yield | -59.73 |